Lexeo Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.06 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 251.05M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Details
| Name | Lexeo Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 63 |
| Founded | 2017 |
| Ipo Date | 2023-11-03 |
| Ceo | R. Townsend |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 11.00 |
| Isin | US52886X1072 |
| Cusip | 52886X107 |
| Cik | 1907108 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| R. Nolan Townsend M.B.A. | Chief Executive Officer and Director |
| Louis Tamayo | Chief Financial Officer and Principal Accounting Officer |
| Dr. Ronald G. Crystal M.D. | Co-Founder, Chief Scientific Advisor and Member of Scientific Advisory Board |
| Dr. Jose Manuel Otero Ph.D. | Chief Operating Officer |
| Dr. Narinder P. Bhalla FACC, FSCAI, M.D. | Chief Medical Officer |
| Keith Wonnacott | Senior Vice President of Regulatory Affairs |
| Ashley Kaplowitz | Head of Capital Markets |
| Ryan McHenry | Vice President and Corporate Controller |
Contact
| Address | 345 Park Avenue South, 6th Floor, New York, New York 10010, United States |
| Phone | 212 547 9879 |
| Website | https://www.lexeotx.com |